Woody Joseph Fralin purchased $85K of RCEL

Woody Joseph Fralin purchased 20,000 shares of AVITA Medical, Inc. (RCEL) at an average of $4.25 ($4.18–$4.34) across 4 trades over 2026-06-01 to 2026-06-02.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 3, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RCEL
Bullish
medium confidence
Mentioned
$RCEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELBullishLow
01

Why it matters

A director's purchase may be interpreted as confidence, but the amount ($85K) is modest relative to typical market volume.

02

Market read

Primary insider purchase with limited material impact; may generate slight positive sentiment.

03

What to watch

If the director has additional undisclosed holdings or upcoming corporate actions, the trade could be more material.

Relevance 4/10Novelty 4/10Timing: post-filing today

Background

SEC Form 4 filing discloses insider transactions. Avita Medical (RCEL) is a micro‑cap listed on Nasdaq.

Company-level read

Ticker impact

$RCELBullishMedium confidence
Context

Director Woody Joseph Fralin bought 20,000 shares for $84,936, increasing his stake to 20,000 shares.

Expected impact

likely slight upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is small relative to market cap but represents a director buying at $4.25 average, which can be viewed as a positive signal.

Market effects

Minimal impact on the medical device sector; only a micro‑cap insider trade.

Limited to U.S. over‑the‑counter investors in RCEL.

Low

Counterpoint

The purchase size is too small to move the stock; traders may ignore it.

Key entities

  • Avita Medical, Inc.

    Issuer of the shares purchased.

  • Woody Joseph Fralin

    Director of Avita Medical who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.